125 related articles for article (PubMed ID: 3881263)
21. [Pharma-clinics. The drug of the month. Dipyridamole-acetylsalicylic acid combination (Aggrenox)].
Scheen AJ
Rev Med Liege; 2000 Oct; 55(10):957-9. PubMed ID: 11244807
[TBL] [Abstract][Full Text] [Related]
22. Livedo vasculitis. Therapy with pentoxifylline.
Sams WM
Arch Dermatol; 1988 May; 124(5):684-7. PubMed ID: 3364993
[TBL] [Abstract][Full Text] [Related]
23. Early treatment with aspirin plus extended-release dipyridamole for transient ischaemic attack or ischaemic stroke within 24 h of symptom onset (EARLY trial): a randomised, open-label, blinded-endpoint trial.
Dengler R; Diener HC; Schwartz A; Grond M; Schumacher H; Machnig T; Eschenfelder CC; Leonard J; Weissenborn K; Kastrup A; Haberl R;
Lancet Neurol; 2010 Feb; 9(2):159-66. PubMed ID: 20060783
[TBL] [Abstract][Full Text] [Related]
24. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia.
Bousser MG; Eschwege E; Haguenau M; Lefaucconnier JM; Thibult N; Touboul D; Touboul PJ
Stroke; 1983; 14(1):5-14. PubMed ID: 6401878
[TBL] [Abstract][Full Text] [Related]
25. On the assessment of the efficacy of pentoxifylline (Trental).
Rössner M; Müller R
J Med; 1987; 18(1):1-15. PubMed ID: 3298515
[TBL] [Abstract][Full Text] [Related]
26. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS).
Diener HC; Sacco R; Yusuf S; ;
Cerebrovasc Dis; 2007; 23(5-6):368-80. PubMed ID: 17337887
[TBL] [Abstract][Full Text] [Related]
27. Post-ischemic treatment of pentoxifylline reduces cortical not striatal infarct volume in transient model of focal cerebral ischemia in rat.
Vakili A; Zahedi khorasani M
Brain Res; 2007 May; 1144():186-91. PubMed ID: 17320054
[TBL] [Abstract][Full Text] [Related]
28. Controlled clinical trial of pentoxifylline versus cinnarizine in the treatment of labyrinthine disorders.
Ganança MM; Mangabeira Albernaz PL; Caovilla HH; Ito YI
Pharmatherapeutica; 1988; 5(3):170-6. PubMed ID: 3283777
[TBL] [Abstract][Full Text] [Related]
29. [After stroke or TIA. Double protection by second platelet inhibitor].
MMW Fortschr Med; 2003 Dec; 145(50):57. PubMed ID: 14963978
[No Abstract] [Full Text] [Related]
30. Aggrenox: a fixed-dose combination of aspirin and dipyridamole.
Lenz TL; Hilleman DE
Ann Pharmacother; 2000 Nov; 34(11):1283-90. PubMed ID: 11098344
[TBL] [Abstract][Full Text] [Related]
31. [Secondary prevention of ischemic insult and transient cerebral ischemia. Is ASS alone enough?].
Diener HC
MMW Fortschr Med; 2003 May; 145 Suppl 2():111. PubMed ID: 14579505
[No Abstract] [Full Text] [Related]
32. A randomized trial of aspirin or heparin in hospitalized patients with recent transient ischemic attacks. A pilot study.
Biller J; Bruno A; Adams HP; Godersky JC; Loftus CM; Mitchell VL; Banwart KJ; Jones MP
Stroke; 1989 Apr; 20(4):441-7. PubMed ID: 2648650
[TBL] [Abstract][Full Text] [Related]
33. Design of ESPRIT: an international randomized trial for secondary prevention after non-disabling cerebral ischaemia of arterial origin. European/Australian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) group.
De Schryver EL
Cerebrovasc Dis; 2000; 10(2):147-50. PubMed ID: 10686454
[TBL] [Abstract][Full Text] [Related]
34. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial.
; Halkes PH; van Gijn J; Kappelle LJ; Koudstaal PJ; Algra A
Lancet; 2006 May; 367(9523):1665-73. PubMed ID: 16714187
[TBL] [Abstract][Full Text] [Related]
35. Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].
Kirshner HS
Int J Clin Pract; 2007 Oct; 61(10):1739-48. PubMed ID: 17877660
[TBL] [Abstract][Full Text] [Related]
36. Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan.
Takahashi S; Mizuno O; Sakaguchi T; Yamada T; Inuyama L
Adv Ther; 2014 Jan; 31(1):118-29. PubMed ID: 24385407
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events.
Gengo FM; Rainka M; Robson M; Gengo MF; Forrest A; Hourihane M; Bates V
J Clin Pharmacol; 2008 Mar; 48(3):335-43. PubMed ID: 18223144
[TBL] [Abstract][Full Text] [Related]
38. A randomized trial of E5510 versus aspirin in patients with transient ischemic attacks. The Japanese E5510 TIA study-1 (JETS-1) Group.
Maruyama S; Uchiyama S; Tohgi H; Hirai S; Ikeda Y; Shinohara Y; Matsuda T; Fujishima M; Kameyama M
Angiology; 1995 Nov; 46(11):999-1008. PubMed ID: 7486235
[TBL] [Abstract][Full Text] [Related]
39. The European Stroke Prevention Study (ESPS): results by arterial distribution.
Sivenius J; Riekkinen PJ; Smets P; Laakso M; Lowenthal A
Ann Neurol; 1991 Jun; 29(6):596-600. PubMed ID: 1892362
[TBL] [Abstract][Full Text] [Related]
40. Secondary stroke prevention with antiplatelet therapy with emphasis on the cardiac patient: a neurologist's view.
Gebel JM
J Am Coll Cardiol; 2005 Sep; 46(5):752-5. PubMed ID: 16139120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
